Brepocitinib yields ‘consistent’ improvements in cutaneous dermatomyositis

Brepocitinib improved skin-specific symptoms of dermatomyositis, according to an analysis of the phase 3 VALOR trial published in JAMA Dermatology. These findings, which included rapid and durable reductions in itch and skin disease activity, come after the release of the primary efficacy and safety results in The New England Journal of Medicine and presented at the American Academy of